Suggested remit: To appraise the clinical and cost effectiveness of pemigatinib within its marketing authorisation for treating relapsed or refractory advanced cholangiocarcinoma.
Status In progress
Process STA 2018
ID number 3740

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 27 March 2020 - 28 April 2020

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
29 January 2020 In progress, Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance